S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
The "King Of Quants" sees 10X potential... (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
The "King Of Quants" sees 10X potential... (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Fed's Shocking New Plan to Control Your Money (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
The "King Of Quants" sees 10X potential... (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
The "King Of Quants" sees 10X potential... (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Fed's Shocking New Plan to Control Your Money (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
The "King Of Quants" sees 10X potential... (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
The "King Of Quants" sees 10X potential... (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Fed's Shocking New Plan to Control Your Money (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
The "King Of Quants" sees 10X potential... (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
The "King Of Quants" sees 10X potential... (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Fed's Shocking New Plan to Control Your Money (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament

Mesa Laboratories - MLAB Stock Forecast, Price & News

$170.86
+1.37 (+0.81%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$165.20
$171.58
50-Day Range
$163.15
$203.76
52-Week Range
$114.21
$263.40
Volume
29,174 shs
Average Volume
45,354 shs
Market Capitalization
$914.10 million
P/E Ratio
N/A
Dividend Yield
0.37%
Price Target
$166.00

Mesa Laboratories MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
2.8% Downside
$166.00 Price Target
Short Interest
Bearish
9.16% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$1.16 M Sold Last Quarter
Proj. Earnings Growth
-12.46%
From $6.82 to $5.97 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.84 out of 5 stars

Medical Sector

1002nd out of 1,005 stocks

Process Control Instruments Industry

11th out of 11 stocks


MLAB stock logo

About Mesa Laboratories (NASDAQ:MLAB) Stock

Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection Control, Instruments, Continuous Monitoring, and Biopharmaceutical Development. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators. The Instrument segment designs, manufactures, and markets control instruments and disposable products used in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. The Biopharmaceutical Development segment develops and sells automated systems for protein analysis and peptide synthesis solutions. The Continuous Monitoring segment includes development of systems used to monitor various environmental parameters. The company was founded by Luke R. Schmieder on March 26, 1982 and is headquartered in Lakewood, CO.

Receive MLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesa Laboratories and its competitors with MarketBeat's FREE daily newsletter.

MLAB Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Mesa Labs (MLAB) Tops Q3 Earnings Estimates
Earnings Outlook For Mesa Laboratories
Is Mesa Laboratories (MLAB) a Growing Stock?
Bull of the Day: Mesa Labs (MLAB)
Here’s Why Mesa Laboratories (MLAB) Declined in Q3
Why Mesa Laboratories (MLAB) Stock Is Getting Hammered Today
See More Headlines
Receive MLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesa Laboratories and its competitors with MarketBeat's FREE daily newsletter.

MLAB Company Calendar

Last Earnings
5/31/2021
Ex-Dividend for 3/15 Dividend
2/27/2023
Dividend Payable
3/15/2023
Today
3/26/2023
Fiscal Year End
3/31/2023
Next Earnings (Confirmed)
5/25/2023

Industry, Sector and Symbol

Industry
Process control instruments
Sub-Industry
Electronic Equipment & Instruments
Sector
Medical
Current Symbol
NASDAQ:MLAB
CUSIP
59064R10
Employees
506
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$166.00
High Stock Price Forecast
$166.00
Low Stock Price Forecast
$166.00
Forecasted Upside/Downside
-2.8%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$1.87 million
Pretax Margin
-0.07%

Debt

Sales & Book Value

Annual Sales
$184.34 million
Cash Flow
$11.35 per share
Book Value
$75.07 per share

Miscellaneous

Free Float
5,052,000
Market Cap
$914.10 million
Optionable
Not Optionable
Beta
0.70

Key Executives

  • John James Sullivan
    Chairman
  • Gary M. OwensGary M. Owens
    President, CEO, COO & Director
  • John V. SakysJohn V. Sakys
    CFO, Treasurer & Chief Accounting Officer
  • Peter Jung
    Vice President-Strategy & Corporate Development
  • Brian Archbold
    Senior Vice President-Continuous Improvement













MLAB Stock - Frequently Asked Questions

What is Mesa Laboratories' stock price forecast for 2023?

0 analysts have issued 12 month price objectives for Mesa Laboratories' stock. Their MLAB share price forecasts range from $166.00 to $166.00. On average, they predict the company's share price to reach $166.00 in the next year. This suggests that the stock has a possible downside of 2.8%.
View analysts price targets for MLAB
or view top-rated stocks among Wall Street analysts.

How have MLAB shares performed in 2023?

Mesa Laboratories' stock was trading at $166.21 at the beginning of 2023. Since then, MLAB shares have increased by 2.8% and is now trading at $170.86.
View the best growth stocks for 2023 here
.

When is Mesa Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 25th 2023.
View our MLAB earnings forecast
.

How were Mesa Laboratories' earnings last quarter?

Mesa Laboratories, Inc. (NASDAQ:MLAB) issued its earnings results on Monday, May, 31st. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.91 by $0.17. The medical instruments supplier earned $37.96 million during the quarter, compared to analyst estimates of $34.92 million. Mesa Laboratories had a positive trailing twelve-month return on equity of 8.49% and a negative net margin of 0.66%.

How often does Mesa Laboratories pay dividends? What is the dividend yield for Mesa Laboratories?

Mesa Laboratories declared a quarterly dividend on Tuesday, January 3rd. Shareholders of record on Tuesday, February 28th will be given a dividend of $0.16 per share on Wednesday, March 15th. This represents a $0.64 dividend on an annualized basis and a yield of 0.37%. The ex-dividend date of this dividend is Monday, February 27th.
Read our dividend analysis for MLAB
.

Is Mesa Laboratories a good dividend stock?

Mesa Laboratories (NASDAQ:MLAB) pays an annual dividend of $0.64 per share and currently has a dividend yield of 0.38%.
Read our dividend analysis for MLAB.

What is Gary Owens' approval rating as Mesa Laboratories' CEO?

5 employees have rated Mesa Laboratories Chief Executive Officer Gary Owens on Glassdoor.com. Gary Owens has an approval rating of 51% among the company's employees. This puts Gary Owens in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Mesa Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesa Laboratories investors own include NVIDIA (NVDA), Verizon Communications (VZ), Intel (INTC), Alibaba Group (BABA), Altria Group (MO), Micron Technology (MU), Exxon Mobil (XOM), AbbVie (ABBV), Advanced Micro Devices (AMD) and Becton, Dickinson and (BDX).

What is Mesa Laboratories' stock symbol?

Mesa Laboratories trades on the NASDAQ under the ticker symbol "MLAB."

Who are Mesa Laboratories' major shareholders?

Mesa Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Conestoga Capital Advisors LLC (10.76%), Morgan Stanley (4.93%), Geneva Capital Management LLC (3.59%), Principal Financial Group Inc. (2.82%), Eagle Asset Management Inc. (1.87%) and Geode Capital Management LLC (1.79%). Insiders that own company stock include Brian David Archbold, David M Kelly, Evan Guillemin, Gary M Owens, Gregory Dinoia, John Bradley Schmieder, John James Sullivan, John Sakys and Shannon Hall.
View institutional ownership trends
.

How do I buy shares of Mesa Laboratories?

Shares of MLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mesa Laboratories' stock price today?

One share of MLAB stock can currently be purchased for approximately $170.86.

How much money does Mesa Laboratories make?

Mesa Laboratories (NASDAQ:MLAB) has a market capitalization of $914.10 million and generates $184.34 million in revenue each year. The medical instruments supplier earns $1.87 million in net income (profit) each year or ($0.29) on an earnings per share basis.

How many employees does Mesa Laboratories have?

The company employs 506 workers across the globe.

How can I contact Mesa Laboratories?

Mesa Laboratories' mailing address is 12100 W 6TH AVE, LAKEWOOD CO, 80228. The official website for the company is www.mesalabs.com. The medical instruments supplier can be reached via phone at (303) 987-8000, via email at investorrelations@mesalabs.com, or via fax at 303-987-8989.

This page (NASDAQ:MLAB) was last updated on 3/26/2023 by MarketBeat.com Staff